Journal
JOURNAL OF MOVEMENT DISORDERS
Volume 14, Issue 3, Pages 184-192Publisher
KOREAN MOVEMENT DISORDERS SOC
DOI: 10.14802/jmd.21046
Keywords
Angiotensin converting enzyme 2; COVID-19; Parkinson's disease; Substantia nigra pars compacta
Categories
Ask authors/readers for more resources
The review highlights the direct impact of SARS-CoV-2 on the brain through various pathways and its aggravation of PD in affected patients. Studies have shown that PD patients are more vulnerable to COVID-19, and the sudden lifestyle changes and lockdowns caused by the pandemic have heightened the difficulties faced by PD patients.
There is an extensive debate on the neurological consequences of 2019 novel coronavirus disease (COVID-19) and its impact on Parkinson's disease (PD) patients, which seems to puzzle neurologists. Links between viral infections and PD have long been suspected and studied, but the exact relationship remains elusive. Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the brain through multiple routes and has a direct impact on the brain, cumulative damage occurs due to the activation of proinflammatory cytokines and chemokines. SARS-CoV-2 seems to aggravate PD due to its effects on alpha-synuclein, mitochondria' dysfunction, and dopamine depletion. A few studies have even highlighted the higher vulnerability of PD patients to COVID-19. The sudden dramatic change in lifestyle caused by the pandemic and the widespread lockdowns that were implemented have added to the hidden sorrows of PD patients, as they already have a compromised mechanism for coping with stress. This review summarizes insights from basic science and the clinical effect of SARS-CoV-2 infection on the human brain, with a specific focus on PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available